一分钟看懂
这是一项关于卵巢癌的III 期研究，登记的药物或干预包括Rina-S；Paclitaxel；Topotecan；Pegylated liposomal doxorubicin (PLD)；Gemcitabine，当前状态为研究进行中，已停止招募。登记地点显示中国广州、西安、长春、Hanzhou等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Rina-S；Paclitaxel；Topotecan；Pegylated liposomal doxorubicin (PLD)；Gemcitabine · III 期
登记条件中文摘要
登记的基本范围为女性，年龄18 岁；另列出8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出7项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Sun Yat-Sen University Cancer Center · 广州
- The First Affiliated Hospital of Xi'an Jiaotong University · 西安
- The First Hospital of Jilin University · 长春
- Zhejiang Cancer Hospital · Hanzhou
- Fudan University Shanghai Cancer Center · 上海
- Tianjin Medical University Cancer Institute & Hospital · 天津
- Henan Cancer Hospital - Zhengzhou University · 郑州
公开的入选条件
- * Participants must have histologically or cytologically confirmed high grade serous or endometrioid epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
- * Participants may be enrolled regardless of FRα expression level.
- * Participants must have received 1 to 4 prior lines of therapy. Participants must have progressed radiographically on or after their most recent line of therapy.
- * Participants must have received prior treatment with the following therapies:
- Platinum chemotherapy
- Prior bevacizumab (or biosimilar) treatment is required, if labeled and available as standard of care per institutional guidelines, unless the participant has a documented contraindication or unless the participant is not eligible for treatment with bevacizuma
- Participants with known or suspected deleterious germline or somatic breast cancer gene (BRCA) mutations and who achieved a complete or partial response to platinum-based chemotherapy must have been treated with a poly ADP-ribose polymerase (PARP) inhibitor as
- Mirvetuximab soravtansine, if:
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06619236；登记信息更新于 2026-09-28。